Anzeige
Mehr »
Sonntag, 01.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Insider Monkey

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
SaOcular Therapeutix, Inc. (OCUL): A Bull Case Theory
SaPlanet Labs PBC (PL): A Bull Case Theory
SaFluor Corporation (FLR): A Bull Case Theory
SaGenpact Limited (G): A Bull Case Theory
SaGameStop Corp. (GME): A Bull Case Theory
SaHere's What Analysts Are Saying About PG&E Corporation (PCG)
SaWhat Does the Street Think About Lionsgate Studios Corp. (LION) Post Earnings?
SaClear Street Cuts PT on Cipher Digital (CIFR) to $32 From $34 - Here's Why
SaWhy are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?
SaSibanye Stillwater (SBSW) Announces Financial Results for the Full Year and Six Months Ended December 31, 2025
Sa14 Value Stocks to Buy With High Dividend Yields
SaThree Megatrends. One Overlooked Stock. Massive Upside
SaGenenta Science SPA (GNTA) Shifting from Biotech to Defense Business
Sa10 Unstoppable Stocks to Buy and Hold for the Next 3 Years
SaCan Ermenegildo Zegna NV (ZGN) Sustain the Momentum with Affluent Consumers?
SaFerrari NV (RACE) Sits on Strong Order Book as New Models Win Traction
SaWhat Is Ahead for Terra Innovatum Global NV (NKLR)'s Micro-Modular Nuclear Reactors
Sa10 Stocks Ending February With a Bang
SaFREE REPORT: Three Megatrends. One Overlooked Stock. Massive Upside
SaNasdaq (NDAQ) Launches New Private Capital Indexes to Standardize Benchmarking for Private Markets
SaMarketAxess (MKTX) Appoints William Quan as CTO to Drive Platform Innovation
SaLemonade (LMND) Reports Record Gross Profit and 53% Revenue Growth in Q4 2025
Sa10 Hot Stocks Under $20 to Buy
SaTrupanion (TRUP) Surpasses $1B in Subscription Revenue and Returns to Profitability in 2025
FrAnalyst Bullish on Cogent (COGT) Amid Expected Drug Approval